D-0268-2019 Class II Terminated

Recalled by Sciegen Pharmaceuticals Inc — Hauppauge, NY

FDA drug recall D-0268-2019 was initiated by Sciegen Pharmaceuticals Inc on Oct 29, 2018 and is designated Class II. Reason for recall: CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product. The recall status is terminated (terminated Sep 25, 2023). Affected quantity: 5,061 HDPE bottles.

Recall details

Product Type
Drugs
Report Date
Nov 28, 2018
Initiation Date
Oct 29, 2018
Termination Date
Sep 25, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,061 HDPE bottles

Product description

Westminister Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 69367-120-01), (b) 90-count bottle (NDC 69367-120-03), Rx Only, Manufactured by ScieGen Pharmaceuticals Inc. Hauppauge, NY 11755, Manufactured for Westminster Pharmaceuticals LLC Olive Branch, MS 20854, Made in the USA.

Reason for recall

CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.

Distribution pattern

Nationwide

Code information

69367-120-01 Irbesartan 150mg Tablets, 30 count bottle B161005A Sep-19 C161002A Feb-20 69367-120-03 Irbesartan 150mg Tablets, 90 count bottle B161005B Sep-19 C161002B Feb-20

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0268-2019
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0268-2019. Report a data issue: hello@regdatalab.com.